CO2020002287A2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
CO2020002287A2
CO2020002287A2 CONC2020/0002287A CO2020002287A CO2020002287A2 CO 2020002287 A2 CO2020002287 A2 CO 2020002287A2 CO 2020002287 A CO2020002287 A CO 2020002287A CO 2020002287 A2 CO2020002287 A2 CO 2020002287A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
active ingredient
compositions
medicine
processes
Prior art date
Application number
CONC2020/0002287A
Other languages
Spanish (es)
Inventor
Stephen John Pethen
Gary Cook
Sally Louise Marsh
Michael Bryan Roe
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713660.7A external-priority patent/GB201713660D0/en
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CO2020002287A2 publication Critical patent/CO2020002287A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas en solución acuosa que comprenden por lo menos un agente de tonicidad no iónico, por lo menos una solución tampón y un ingrediente activo, caracterizadas porque dicho ingrediente activo es un compuesto de la fórmula I (I) caracterizado porque R1-R9 están definidos en el presente documento; los procesos para la preparación de estas composiciones y su uso en medicina, en especial su uso en el tratamiento de las enfermedades oculares.The present invention relates to pharmaceutical compositions in aqueous solution that comprise at least one non-ionic tonicity agent, at least one buffer solution and an active ingredient, characterized in that said active ingredient is a compound of formula I (I) characterized because R1-R9 are defined herein; the processes for the preparation of these compositions and their use in medicine, especially their use in the treatment of ocular diseases.

CONC2020/0002287A 2017-08-11 2020-02-28 Pharmaceutical compositions CO2020002287A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544346P 2017-08-11 2017-08-11
GBGB1713660.7A GB201713660D0 (en) 2017-08-25 2017-08-25 Pharmaceutical compositions
PCT/GB2018/052292 WO2019030540A1 (en) 2017-08-11 2018-08-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CO2020002287A2 true CO2020002287A2 (en) 2020-06-09

Family

ID=70976595

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0002287A CO2020002287A2 (en) 2017-08-11 2020-02-28 Pharmaceutical compositions

Country Status (8)

Country Link
CL (1) CL2020000356A1 (en)
CO (1) CO2020002287A2 (en)
EC (1) ECSP20017939A (en)
IL (1) IL272428A (en)
MX (1) MX2020001356A (en)
PH (1) PH12020500246A1 (en)
RU (1) RU2020109955A (en)
UA (1) UA125537C2 (en)

Also Published As

Publication number Publication date
UA125537C2 (en) 2022-04-13
RU2020109955A (en) 2021-09-14
CL2020000356A1 (en) 2020-06-19
MX2020001356A (en) 2020-03-20
PH12020500246A1 (en) 2021-03-15
IL272428A (en) 2020-03-31
ECSP20017939A (en) 2020-04-22
RU2020109955A3 (en) 2022-01-24

Similar Documents

Publication Publication Date Title
NI201900041A (en) 1, 2, 4-TRIAZOLONES 2, 4, 5-TRISUSTITUIDAS
CL2017002636A1 (en) Compositions comprising a combination of a programmed anti-death antibody 1 (pd-1) and another antibody.
CO2020001244A2 (en) Quinoline derivatives to treat helminth infections
CL2016002812A1 (en) Use of 3-2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl-thiophene-2-carboxylic acid to prepare a medicament useful for treating an eye disease that is uveitis, dry eye or caused by a adenovirus composition formulation.
CL2020002252A1 (en) Ophthalmic formulation.
CO2017011795A2 (en) Topical pharmaceutical compositions
CR20170411A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE N- (3,5-DIMETOXIFENIL) -N- (1-METHYTILE) -N- [3- (1-METHYL-1H-PIRAZOL-4-IL-QUIN OXALIN-6-IL] ETANO-1 , 2-DIAMINE
PE20191650A1 (en) INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION
UY37496A (en) N- [5- (AMINOSULFONYL) -4-METHYL-1,3-TIAZOL-2-IL] -N-METHYL-2- [4- (2-PYRIDINYL) -PHENYL] -ACETAMIDE FREE BASE HEMIHYDRATE MANUFACTURING METHODS AND USES OF THE SAME
CR20180493A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
DOP2019000275A (en) NEW BICYCLIC PIRAZOLE DERIVATIVES
CO2019011546A2 (en) Compounds and methods for the treatment of parasitic diseases
CL2020002891A1 (en) New quinoline derivatives
CL2019003572A1 (en) Low-dose brimonidine combinations and uses thereof.
UY37577A (en) DIHYDROIMIDAZOPIRIDINDIONAS REPLACED
CL2017001840A1 (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using them.
CO2019004004A2 (en) Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
NI201900063A (en) AROMATIC AMIDES OF CARBOXYLIC ACID
AR110250A1 (en) TOPICAL FORMULATION INCLUDING N- [5- (AMINOSULFONIL) -4-METHYL-1,3-TIAZOL-2-IL] -N-METHYL-2- [4- (2-PYRIDINYL) -PHENYL] -ACETAMIDE
CO2020002287A2 (en) Pharmaceutical compositions
CO2022002493A2 (en) 18p-glycyrrhetinic acid nanoemulsion
ECSP19091543A (en) DEVICES FOR INTRAVAGINAL APPLICATION THAT INCLUDE ANTIVIRAL COMPOUNDS
AR086252A1 (en) TOPICAL FORMULATION THAT INCLUDES BECLOMETASONE DIPROPIONATE AS ACTIVE INGREDIENT
EA202091903A1 (en) CRYSTAL FORM OF BITEGAVIR-SODIUM